Clinical Trial

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

Available
View on ClinicalTrials.gov →
Summary
The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 9 locations 2026-05-13
Trial Details
NCT Number NCT07250737
Lead Sponsor Avidity Biosciences, Inc.
Collaborators: Clinigen Healthcare Limited
Conditions Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Muscular Dystrophies +1 more
Updated on ClinicalTrials.gov 2026-08-12